Skip to main content
main-content
Erschienen in: Indian Journal of Hematology and Blood Transfusion 3/2022

30.01.2022 | COVID-19 | Original Article Zur Zeit gratis

SARS-CoV-2 Seroprevalence Among Whole Blood Donors During First Wave of Covid-19 Pandemic in India

verfasst von: Srinivasa Rao Chunchu, Ushasree Ravula, Vikram Kumar Gente, Srinivas Bacchu, S. Pandu Ranga Rao, Srujaleswari Mooli

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

The current study aimed to estimate the seroprevalence of SARS-CoV-2 IgG (S-protein) antibodies along with neutralizing assay (RBD-domain) among the whole blood donors without any prior Covid-19 history or symptoms visiting Blood Centre at a Tertiary care institution, South India amidst the ongoing pandemic. During September 2020 to March 2021, 1034 whole blood donors were enrolled into the study and were screened for anti-SARS-CoV-2 IgG antibodies using Chemiluminescence assay followed by neutralizing antibodies using surrogate neutralization ELISA. The study reported seroprevalence of 49.4%, (95% CI 46.3–52.5) among whole blood donors, with test sensitivity and specificity adjusted prevalence of 54.9% (95% CI 51.5–58.3). Seroprevalence was similar across age groups, gender, voluntary/replacement donations, area of residence, ABO and Rh groups without any statistical significance. However higher IgG antibody responses were found to be elicited in the 30–45 years age group when compared with 18–29 years age group (p value 0.046). This study also analysed the mean neutralizing capacity of SARS-CoV-2 antibodies among 97 blood donors which was 71.9 (SD: + 21.03, range 15.5 to 97.3). Donor samples with SARS-CoV-2 IgG S/Co > 9.5 had significantly higher neutralising capacity (> 68%) when compared with donor samples of S/Co < 9.5 (p value 0.000). Real-time seroprevalence studies will help to know the herd immunityamong the blood donors which will assist in knowing the Covid-19 transmission dynamics, distribution of immunity levels at a particular point in time, immunity gaps, development of novel therapeutics and prioritize the vaccination programmes to high risk individuals.
Literatur
4.
Zurück zum Zitat Ibarrondo FJ et al (2020) Rapid decay of anti SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med 383(11):1085–1087 CrossRef Ibarrondo FJ et al (2020) Rapid decay of anti SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med 383(11):1085–1087 CrossRef
5.
Zurück zum Zitat Winter K, Martinez ME et al (2018) Benefits and challenges in using seroprevalence data to inform models for measles and Rubella elimination. J Infect Dis 218(3):355–364 CrossRef Winter K, Martinez ME et al (2018) Benefits and challenges in using seroprevalence data to inform models for measles and Rubella elimination. J Infect Dis 218(3):355–364 CrossRef
6.
Zurück zum Zitat Murhekar MV, Bhatnagar T, Selvaraju S, Saravanakumar V, Thangaraj JWV et al (2021) ICMR Serosurveillance Group. SARS-CoV-2 antibody seroprevalence in India, August–September, 2020: findings from the second nationwide household serosurvey. Lancet Glob Health 9(3):e257–e266. https://​doi.​org/​10.​1016/​S2214-109X(20)30544-1. Epub 2021 Jan 27. PMID: 33515512; PMCID: PMC7906675 Murhekar MV, Bhatnagar T, Selvaraju S, Saravanakumar V, Thangaraj JWV et al (2021) ICMR Serosurveillance Group. SARS-CoV-2 antibody seroprevalence in India, August–September, 2020: findings from the second nationwide household serosurvey. Lancet Glob Health 9(3):e257–e266. https://​doi.​org/​10.​1016/​S2214-109X(20)30544-1. Epub 2021 Jan 27. PMID: 33515512; PMCID: PMC7906675
10.
Zurück zum Zitat Britton T, Ball F, Trapman P (2020) A mathematical model reveals the influence of population heterogenicity on herd immunity to SARS-CoV-2. Science 369:846–849 CrossRef Britton T, Ball F, Trapman P (2020) A mathematical model reveals the influence of population heterogenicity on herd immunity to SARS-CoV-2. Science 369:846–849 CrossRef
11.
Zurück zum Zitat Aguas R, Corder RM, King JG, Goncalves G, Ferreira MU, Gomes MG (2020) Herd immunity thresholds for SARS-CoV-2 estimated from unfolding epidemics. medRxiv Aguas R, Corder RM, King JG, Goncalves G, Ferreira MU, Gomes MG (2020) Herd immunity thresholds for SARS-CoV-2 estimated from unfolding epidemics. medRxiv
13.
Zurück zum Zitat Wilmes P, Zimmer J, Schulz J, Glod F, Veiber L, Mombaerts L, Rodrigues B, Aalto A, Pastore J, Snoeck CJ, Ollert M, Fagherazzi G, Mossong J, Goncalves J, Skupin A, Nehrbass U (2021) SARS-CoV-2 transmission risk from asymptomatic carriers: Results from a mass screening programme in Luxembourg. Lancet Reg Health Eur 4:100056. https://​doi.​org/​10.​1016/​j.​lanepe.​2021.​100056. Epub 2021 Feb 27. PMID: 33997830; PMCID: PMC7912359 Wilmes P, Zimmer J, Schulz J, Glod F, Veiber L, Mombaerts L, Rodrigues B, Aalto A, Pastore J, Snoeck CJ, Ollert M, Fagherazzi G, Mossong J, Goncalves J, Skupin A, Nehrbass U (2021) SARS-CoV-2 transmission risk from asymptomatic carriers: Results from a mass screening programme in Luxembourg. Lancet Reg Health Eur 4:100056. https://​doi.​org/​10.​1016/​j.​lanepe.​2021.​100056. Epub 2021 Feb 27. PMID: 33997830; PMCID: PMC7912359
15.
16.
Zurück zum Zitat Gupta R, Dwivedi T, Gajendra S, Sahoo B, Gupta SK, Vikas H, Singh AR, Mohan A, Bhatnagar S, Singh S, Wundavalli L, Guleria R (2021) Seroprevalence of antibodies to SARS-CoV-2 in healthcare workers & implications of infection control practice in India. Indian J Med Res 153(1 & 2):207–213. https://​doi.​org/​10.​4103/​ijmr.​IJMR_​3911_​20. PMID: 33642348; PMCID: PMC8184075 Gupta R, Dwivedi T, Gajendra S, Sahoo B, Gupta SK, Vikas H, Singh AR, Mohan A, Bhatnagar S, Singh S, Wundavalli L, Guleria R (2021) Seroprevalence of antibodies to SARS-CoV-2 in healthcare workers & implications of infection control practice in India. Indian J Med Res 153(1 & 2):207–213. https://​doi.​org/​10.​4103/​ijmr.​IJMR_​3911_​20. PMID: 33642348; PMCID: PMC8184075
17.
Zurück zum Zitat Velumani A, Nikam C, Suraweera W, Fu SH, Gelband H, Brown PE, Bogoch I, Nagelkerke N, Jha P (2021) SARS-CoV-2 Seroprevalence in 12 Cities of India from July to December 2020. medRxiv Velumani A, Nikam C, Suraweera W, Fu SH, Gelband H, Brown PE, Bogoch I, Nagelkerke N, Jha P (2021) SARS-CoV-2 Seroprevalence in 12 Cities of India from July to December 2020. medRxiv
24.
Zurück zum Zitat Pollan M, Perez-Gomez B et al (2020) Prevalence of SARS-CoV-2 in spain (ENE-COVID): A nation-wide, population based sero-epidemiological study. The Lancet 396(10250):535–544 CrossRef Pollan M, Perez-Gomez B et al (2020) Prevalence of SARS-CoV-2 in spain (ENE-COVID): A nation-wide, population based sero-epidemiological study. The Lancet 396(10250):535–544 CrossRef
25.
Zurück zum Zitat Vena A, Berruti M, Adessi A, Blumetti P, Brignole M et al (2020) Prevalence of antibodies to SARS-CoV-2 in Italian adults and associated risk factors. J Clin Med 9:E2780 Vena A, Berruti M, Adessi A, Blumetti P, Brignole M et al (2020) Prevalence of antibodies to SARS-CoV-2 in Italian adults and associated risk factors. J Clin Med 9:E2780
26.
Zurück zum Zitat McLaughlin CC, Doll MK, Morrison KT, McLaughlin WL, O'Connor T, Sholukh AM, Bossard EL, Phasouk K, Ford ES, Diem K, Klock AM, Jerome KR, Corey L (2020) High community SARS-CoV-2 antibody seroprevalence in a Ski Resort Community, Blaine County, Idaho, US. Preliminary results. medRxiv [Preprint]. 2020 Jul 21:2020.07.19.20157198. https://​doi.​org/​10.​1101/​2020.​07.​19.​20157198. PMID: 32743610; PMCID: PMC7386534. McLaughlin CC, Doll MK, Morrison KT, McLaughlin WL, O'Connor T, Sholukh AM, Bossard EL, Phasouk K, Ford ES, Diem K, Klock AM, Jerome KR, Corey L (2020) High community SARS-CoV-2 antibody seroprevalence in a Ski Resort Community, Blaine County, Idaho, US. Preliminary results. medRxiv [Preprint]. 2020 Jul 21:2020.07.19.20157198. https://​doi.​org/​10.​1101/​2020.​07.​19.​20157198. PMID: 32743610; PMCID: PMC7386534.
34.
Zurück zum Zitat Wong SS, Yuen KY (2008) The management of coronavirus infections with particular reference to SARS. J AntimicrobChemother 62:437–441 Wong SS, Yuen KY (2008) The management of coronavirus infections with particular reference to SARS. J AntimicrobChemother 62:437–441
36.
Zurück zum Zitat Körper S, Jahrsdörfer B, Corman VM, Pilch J, Wuchter P, Blasczyk R, Müller R, Tonn T, Bakchoul T, Schäfer R, Juhl D, Schwarz T, Gödecke N, Burkhardt T, Schmidt M, Appl T, Eichler H, Klüter H, Drosten C, Seifried E, Schrezenmeier H (2021) Donors for SARS-CoV-2 convalescent plasma for a controlled clinical trial: donor characteristics, content and time course of SARS-CoV-2 neutralizing antibodies. Transfus Med Hemother 48:137–147. https://​doi.​org/​10.​1159/​000515610 CrossRefPubMedPubMedCentral Körper S, Jahrsdörfer B, Corman VM, Pilch J, Wuchter P, Blasczyk R, Müller R, Tonn T, Bakchoul T, Schäfer R, Juhl D, Schwarz T, Gödecke N, Burkhardt T, Schmidt M, Appl T, Eichler H, Klüter H, Drosten C, Seifried E, Schrezenmeier H (2021) Donors for SARS-CoV-2 convalescent plasma for a controlled clinical trial: donor characteristics, content and time course of SARS-CoV-2 neutralizing antibodies. Transfus Med Hemother 48:137–147. https://​doi.​org/​10.​1159/​000515610 CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Casadevall A, Henderson JP, Joyner MJ, Pirofski LA (2021) SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities. J Clin Investig 131(7) Casadevall A, Henderson JP, Joyner MJ, Pirofski LA (2021) SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities. J Clin Investig 131(7)
38.
Zurück zum Zitat Bendezú Palacio A, Parejas Sosa C, Chunga Tume P (2021) Una nueva alternativa: terapia con plasma de convalecientes, posible antídoto en tiempos de COVID-19 [A new alternative: convalescent plasma therapy, possible antidote in times of COVID-19]. Medicina (B Aires) 81(2):307. Spanish. PMID: 33906157 Bendezú Palacio A, Parejas Sosa C, Chunga Tume P (2021) Una nueva alternativa: terapia con plasma de convalecientes, posible antídoto en tiempos de COVID-19 [A new alternative: convalescent plasma therapy, possible antidote in times of COVID-19]. Medicina (B Aires) 81(2):307. Spanish. PMID: 33906157
40.
Zurück zum Zitat Mandal A, Chakrabarty R, Datta SS (2021) Whole blood derived covid convalescent plasma: a practical experience from India. Transf Apher Sci Mandal A, Chakrabarty R, Datta SS (2021) Whole blood derived covid convalescent plasma: a practical experience from India. Transf Apher Sci
42.
Zurück zum Zitat Cunningham AC, Goh HP, Koh D (2020) Treatment of Covid-19: old tricks for new challenges. Crit Care 24:91 CrossRef Cunningham AC, Goh HP, Koh D (2020) Treatment of Covid-19: old tricks for new challenges. Crit Care 24:91 CrossRef
43.
Zurück zum Zitat Piechotta V, Chai KL, Valk SJ, Doree C, Monsef I, Wood EM, Lamikanra A, Kimber C, McQuilten Z, So-Osman C, Estcourt LJ, Skoetz N (2020) Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev 7(7):CD013600. https://​doi.​org/​10.​1002/​14651858.​CD013600.​pub2. Update in: Cochrane Database Syst Rev. 2020 Oct 12;10:CD013600. PMID: 32648959; PMCID: PMC7389743 Piechotta V, Chai KL, Valk SJ, Doree C, Monsef I, Wood EM, Lamikanra A, Kimber C, McQuilten Z, So-Osman C, Estcourt LJ, Skoetz N (2020) Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev 7(7):CD013600. https://​doi.​org/​10.​1002/​14651858.​CD013600.​pub2. Update in: Cochrane Database Syst Rev. 2020 Oct 12;10:CD013600. PMID: 32648959; PMCID: PMC7389743
Metadaten
Titel
SARS-CoV-2 Seroprevalence Among Whole Blood Donors During First Wave of Covid-19 Pandemic in India
verfasst von
Srinivasa Rao Chunchu
Ushasree Ravula
Vikram Kumar Gente
Srinivas Bacchu
S. Pandu Ranga Rao
Srujaleswari Mooli
Publikationsdatum
30.01.2022
Verlag
Springer India
Schlagwort
COVID-19
Erschienen in
Indian Journal of Hematology and Blood Transfusion / Ausgabe 3/2022
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-021-01512-y